RU2007138263A - Противовоспалительные соединения - Google Patents
Противовоспалительные соединения Download PDFInfo
- Publication number
- RU2007138263A RU2007138263A RU2007138263/15A RU2007138263A RU2007138263A RU 2007138263 A RU2007138263 A RU 2007138263A RU 2007138263/15 A RU2007138263/15 A RU 2007138263/15A RU 2007138263 A RU2007138263 A RU 2007138263A RU 2007138263 A RU2007138263 A RU 2007138263A
- Authority
- RU
- Russia
- Prior art keywords
- steroid sulfatase
- sulfatase inhibitor
- pharmaceutical composition
- treatment
- inflammatory
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract 3
- 230000003110 anti-inflammatory effect Effects 0.000 title 1
- 229940123142 Steroid sulfatase inhibitor Drugs 0.000 claims abstract 8
- 208000027866 inflammatory disease Diseases 0.000 claims abstract 4
- 238000000034 method Methods 0.000 claims abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 4
- 239000002260 anti-inflammatory agent Substances 0.000 claims abstract 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims abstract 2
- 238000004519 manufacturing process Methods 0.000 claims abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0505541.3 | 2005-03-17 | ||
| GBGB0505541.3A GB0505541D0 (en) | 2005-03-17 | 2005-03-17 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2007138263A true RU2007138263A (ru) | 2009-04-27 |
Family
ID=34531452
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007138263/15A RU2007138263A (ru) | 2005-03-17 | 2006-03-15 | Противовоспалительные соединения |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20090227620A1 (enExample) |
| EP (1) | EP1861098A1 (enExample) |
| JP (1) | JP2008533079A (enExample) |
| KR (1) | KR20070113226A (enExample) |
| CN (1) | CN101137375A (enExample) |
| AU (1) | AU2006224796A1 (enExample) |
| BR (1) | BRPI0607795A2 (enExample) |
| CA (1) | CA2599470A1 (enExample) |
| GB (1) | GB0505541D0 (enExample) |
| MX (1) | MX2007011320A (enExample) |
| RU (1) | RU2007138263A (enExample) |
| WO (1) | WO2006097292A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA200900960A1 (ru) * | 2007-01-31 | 2010-02-26 | Новартис Аг | Производные пиперидинацетамида для лечения воспалительных или аллергических заболеваний |
| CA2698814A1 (en) | 2007-09-17 | 2009-03-26 | Preglem S.A. | Treatment of oestrogen dependant conditions in pre-menopausal women |
| TW200936136A (en) * | 2008-01-28 | 2009-09-01 | Sanofi Aventis | Tetrahydroquinoxaline urea derivatives, their preparation and their therapeutic application |
| ES2555260T3 (es) | 2010-06-15 | 2015-12-30 | Bayer Intellectual Property Gmbh | Derivados de diamida de ácido antranílico |
| CN102657642B (zh) * | 2012-04-24 | 2014-01-15 | 广东省农业科学院兽医研究所 | Irosustat在制备抗柔嫩艾美耳球虫药物中的应用 |
| CA2874621A1 (en) | 2012-05-22 | 2013-11-28 | Genentech, Inc. | N-substituted benzamides and their use in the treatment of pain |
| CN107417601A (zh) * | 2017-04-06 | 2017-12-01 | 成都弥贝生物科技有限公司 | 具有抗菌活性的取代2‑酰胺磺酰基‑4,6‑芳基吡啶 |
| KR102458689B1 (ko) * | 2020-07-08 | 2022-10-25 | 원광대학교산학협력단 | 피페리딘 화합물 및 이의 제조 방법 |
| WO2025079965A1 (ko) * | 2023-10-10 | 2025-04-17 | 주식회사 넥시온바이오텍 | 치주 질환의 예방 또는 치료용 조성물 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9807779D0 (en) * | 1998-04-09 | 1998-06-10 | Ciba Geigy Ag | Organic compounds |
| GB0020498D0 (en) * | 2000-08-18 | 2000-10-11 | Sterix Ltd | Compound |
| US6986938B2 (en) * | 2001-10-03 | 2006-01-17 | A & A Manufacturing Co., Inc. | Bellows with molded panels |
| AR037097A1 (es) * | 2001-10-05 | 2004-10-20 | Novartis Ag | Compuestos acilsulfonamidas, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de un medicamento |
| AR039156A1 (es) * | 2002-03-28 | 2005-02-09 | Novartis Ag | Amidas del acido piperidinilamino sulfamico o piperazinil sulfamico y su uso para la manufactura de un medicamento en enfermedades mediadas por la accion de la sulfatasa esteroide |
| AR041952A1 (es) * | 2002-11-14 | 2005-06-01 | Novartis Ag | N-sulfonilaminotiazol |
-
2005
- 2005-03-17 GB GBGB0505541.3A patent/GB0505541D0/en not_active Ceased
-
2006
- 2006-03-15 JP JP2008501223A patent/JP2008533079A/ja active Pending
- 2006-03-15 EP EP06707567A patent/EP1861098A1/en not_active Withdrawn
- 2006-03-15 CA CA002599470A patent/CA2599470A1/en not_active Abandoned
- 2006-03-15 AU AU2006224796A patent/AU2006224796A1/en not_active Abandoned
- 2006-03-15 CN CNA2006800080245A patent/CN101137375A/zh active Pending
- 2006-03-15 US US11/908,895 patent/US20090227620A1/en not_active Abandoned
- 2006-03-15 RU RU2007138263/15A patent/RU2007138263A/ru not_active Application Discontinuation
- 2006-03-15 BR BRPI0607795-1A patent/BRPI0607795A2/pt not_active IP Right Cessation
- 2006-03-15 KR KR1020077021073A patent/KR20070113226A/ko not_active Withdrawn
- 2006-03-15 MX MX2007011320A patent/MX2007011320A/es not_active Application Discontinuation
- 2006-03-15 WO PCT/EP2006/002382 patent/WO2006097292A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0607795A2 (pt) | 2009-06-13 |
| MX2007011320A (es) | 2007-11-08 |
| US20090227620A1 (en) | 2009-09-10 |
| AU2006224796A1 (en) | 2006-09-21 |
| JP2008533079A (ja) | 2008-08-21 |
| CN101137375A (zh) | 2008-03-05 |
| KR20070113226A (ko) | 2007-11-28 |
| WO2006097292A1 (en) | 2006-09-21 |
| EP1861098A1 (en) | 2007-12-05 |
| GB0505541D0 (en) | 2005-04-27 |
| CA2599470A1 (en) | 2006-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200870254A1 (ru) | Способ лечения воспалительных заболеваний | |
| BRPI0508561A (pt) | 3-'4-heterociclil-1,2,3-triazol-1-il-n-aril-benzamidas como inibidores da produção de citocinas para o tratamento de doenças inflamatórias crÈnicas | |
| NO20075042L (no) | Farmasoytisk sammensetning innbefattende en omega-karboksyarylsubstituert difenylurea for behandling av cancer | |
| WO2008022256A3 (en) | Methods and compositions for preventing or treating age-related diseases | |
| MY139577A (en) | Anti-inflammatory androstane derivative | |
| EP2331095A4 (en) | CYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF | |
| BRPI0513843A (pt) | composto ou um sal ou solvato ou uma pró-droga farmaceuticamente aceitável do mesmo, composição farmacêutica, forma de dosagem, uso de um composto, e, sal de cloridrato | |
| BR112015029512A2 (pt) | derivados de pirazolopirrolidina e seu uso no tratamento de doenças | |
| BR112014004845A2 (pt) | pelo menos uma entidade química; pelo menos um composto; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada | |
| ATE444066T1 (de) | Liganden für den cannabinoidrezeptoren | |
| MX2010009623A (es) | Derivados de 1-bencil-3-hidroximetilindazol novedosos y su uso en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40. | |
| UA107578C2 (uk) | Комбінована терапія при лікуванні діабету | |
| BR112014004741A2 (pt) | pelo menos uma entidade química; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada | |
| AU2012286851A8 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| MX2010009625A (es) | Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40. | |
| PH12020551911A1 (en) | Use of riluzole oral disintigrating tablets for treating diseases | |
| MX2010009624A (es) | Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1. | |
| WO2007062093A3 (en) | Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor | |
| MX2024007642A (es) | Uso de tabletas de desintegracion oral de riluzol para tratar enfermedades. | |
| MY148125A (en) | Compounds | |
| WO2006083780A3 (en) | Glucuronidated nebivolol | |
| AR048336A1 (es) | Hidrocloruro de (4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il)-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos | |
| BR0315462A (pt) | Composto, composição farmacêutica, uso de um composto, método para o tratamento de um sujeito que sofre de uma condição patológica ou de doença susceptìvel de alìvio por antagonismo de receptores de ltd4 e produto de combinação | |
| WO2007057221A3 (en) | Pharmaceutical compositions for the treatment of inflammatory and obstructive airways diseases | |
| AR064543A1 (es) | Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20100716 |